USA: Cancer Therapy Manufacturing Partnership to Promote Understanding of T Cell Biology
Thermo Fisher Scientific and biotechnology company Lyell Immunopharma are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients.
Waltham/USA — The fitness of T cells poses a challenge in manufacturing cell therapies. To overcome this hurdle, Thermo Fisher Scientific and Lyell Immunopharma have formed a manufacturing partnership. The cooperation is also intended to support Lyell with the development of an integrated yet flexible cGMP-compliant platform including reagents, consumables and instrumentation.
The intent of this strategic partnership is to gain access and insights into emerging and existing technologies to improve the robustness and consistency of manufacturing operations. This alliance is also to provide the opportunity for further strategic collaboration in supply chain and commercialization pathways.